These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment failures with levodopa in Parkinsonism. Lieberman AN; Goodgold AL; Goldstein M Neurology; 1972 Nov; 22(11):1205-10. PubMed ID: 4673563 [No Abstract] [Full Text] [Related]
4. Plasma concentration of levodopa in patients with Parkinson's disease. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1973; 10(5):301-10. PubMed ID: 4789106 [No Abstract] [Full Text] [Related]
5. MK 486 and levodopa in treatment of Parkinsonism. Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885 [No Abstract] [Full Text] [Related]
6. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542 [No Abstract] [Full Text] [Related]
8. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine. Holden EM; Brody JA; Chase TN Neurology; 1974 Mar; 24(3):263-5. PubMed ID: 4855953 [No Abstract] [Full Text] [Related]
9. Treatment of Parkinson's disease with Levodopa. Calhoun CL J Natl Med Assoc; 1972 Nov; 64(6):516-7 passim. PubMed ID: 4639943 [No Abstract] [Full Text] [Related]
10. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease. Tyce GM; Muenter MD; Owen CA Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103 [No Abstract] [Full Text] [Related]
11. Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome. Langrall HM; Joseph C Clin Pharmacol Ther; 1971; 12(2):323-31. PubMed ID: 4930865 [No Abstract] [Full Text] [Related]
12. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
13. Ro 4-4602 and levodopa in the treatment of Parkinsonism. Miller EM; Wiener L Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107 [No Abstract] [Full Text] [Related]
14. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Bauer RB; McHenry JT Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417 [No Abstract] [Full Text] [Related]
15. Pyridoxine, DOPA, and Parkinsonism. Yahr MD; Duvoisin RC; Côté L; Cohen G Adv Biochem Psychopharmacol; 1972; 4():185-94. PubMed ID: 4555927 [No Abstract] [Full Text] [Related]
16. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Tolosa ES; Martin WE; Cohen HP; Jacobson RL Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646 [TBL] [Abstract][Full Text] [Related]
17. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Bennett JP; Landow ER; Schuh LA Neurology; 1993 Aug; 43(8):1551-5. PubMed ID: 8043043 [TBL] [Abstract][Full Text] [Related]
19. The Eaton collaborative study of levodopa therapy in parkinsonism: a summary. Keenan RE Neurology; 1970 Dec; 20(12):Suppl:46-65. PubMed ID: 5529915 [No Abstract] [Full Text] [Related]